FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904657106> ?p ?o ?g. }

• W2904657106 endingPage "173.e13" @default.
• W2904657106 startingPage "155" @default.
• W2904657106 abstract "In observational studies of patients switched from stable treatment with an originator monoclonal antibody (mAb) to a biosimilar, higher rates of biosimilar discontinuation versus those observed in blinded switching studies have been reported. Because this observation relates to the real-world setting, it has been suggested that switching outside of clinical trials may be associated with nocebo effects. However, real-world data on drug discontinuation and nocebo effects after switching to mAb biosimilars remain limited. This systematic review collated information from switching studies regarding discontinuation rates of biosimilar mAbs and investigated the subjectivity of reasons for discontinuation to determine the impact of potential nocebo responses.MEDLINE (via PubMed), EMBASE, Cochrane Library, and abstract databases of selected congresses were screened for reports of mAb switching studies with a minimum post-switch follow-up ≥6 months and accessible information on discontinuation rates.A total of 14 observational studies were included, all of which involved a switch to CT-P13. Ten interventional studies involving a switch to other biosimilar mAbs were excluded from the analysis because nocebo effects relate to the observational setting only. Eleven studies (78.6%) reported biosimilar discontinuation rates that were higher than expected based on data pertaining to long-term use of the originator infliximab and clinical trials involving a switch to CT-P13 (>10% per year; range, 12.2%-28.2%). Eight studies attributed a proportion of discontinuations to subjective disease worsening or subjective adverse events. Subjective adverse event reports were identified in 7 of the observational studies.Discontinuation rates of biosimilar mAbs may increase due to subjective effects after switching from an originator mAb. These findings highlight the need for further patient education and well-designed, observational switching studies as well as the collection and analysis of identifiable pharmacovigilance and postmarketing data of biologics, including biosimilars. The collection of real-world results is particularly pertinent for mAbs other than CT-P13, for which there is currently a lack of observational switching data." @default.
• W2904657106 created "2018-12-22" @default.
• W2904657106 creator A5006346169 @default.
• W2904657106 creator A5068763748 @default.
• W2904657106 date "2019-01-01" @default.
• W2904657106 modified "2023-10-15" @default.
• W2904657106 title "Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review" @default.
• W2904657106 cites W2079590652 @default.
• W2904657106 cites W2097892010 @default.
• W2904657106 cites W2106152050 @default.
• W2904657106 cites W2114488753 @default.
• W2904657106 cites W2124227426 @default.
• W2904657106 cites W2330425005 @default.
• W2904657106 cites W2342464058 @default.
• W2904657106 cites W2345220764 @default.
• W2904657106 cites W2508045778 @default.
• W2904657106 cites W2593580677 @default.
• W2904657106 cites W2610308940 @default.
• W2904657106 cites W2613299853 @default.
• W2904657106 cites W2615184173 @default.
• W2904657106 cites W2623304866 @default.
• W2904657106 cites W2623636343 @default.
• W2904657106 cites W2741340135 @default.
• W2904657106 cites W2748244654 @default.
• W2904657106 cites W2751387666 @default.
• W2904657106 cites W2762604306 @default.
• W2904657106 cites W2764082441 @default.
• W2904657106 cites W2766356122 @default.
• W2904657106 cites W2766388803 @default.
• W2904657106 cites W2767179430 @default.
• W2904657106 cites W2768187732 @default.
• W2904657106 cites W2774116866 @default.
• W2904657106 cites W2778747082 @default.
• W2904657106 cites W2784409714 @default.
• W2904657106 cites W2790246629 @default.
• W2904657106 cites W2800677642 @default.
• W2904657106 cites W2802364203 @default.
• W2904657106 cites W2804391440 @default.
• W2904657106 cites W2885292041 @default.
• W2904657106 cites W2885872617 @default.
• W2904657106 doi "https://doi.org/10.1016/j.clinthera.2018.11.002" @default.
• W2904657106 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30551802" @default.
• W2904657106 hasPublicationYear "2019" @default.
• W2904657106 type Work @default.
• W2904657106 sameAs 2904657106 @default.
• W2904657106 citedByCount "26" @default.
• W2904657106 countsByYear W29046571062019 @default.
• W2904657106 countsByYear W29046571062020 @default.
• W2904657106 countsByYear W29046571062021 @default.
• W2904657106 countsByYear W29046571062022 @default.
• W2904657106 countsByYear W29046571062023 @default.
• W2904657106 crossrefType "journal-article" @default.
• W2904657106 hasAuthorship W2904657106A5006346169 @default.
• W2904657106 hasAuthorship W2904657106A5068763748 @default.
• W2904657106 hasBestOaLocation W29046571061 @default.
• W2904657106 hasConcept C126322002 @default.
• W2904657106 hasConcept C142724271 @default.
• W2904657106 hasConcept C177713679 @default.
• W2904657106 hasConcept C197934379 @default.
• W2904657106 hasConcept C204787440 @default.
• W2904657106 hasConcept C23131810 @default.
• W2904657106 hasConcept C27081682 @default.
• W2904657106 hasConcept C2776478404 @default.
• W2904657106 hasConcept C2778360308 @default.
• W2904657106 hasConcept C2778715236 @default.
• W2904657106 hasConcept C2909182145 @default.
• W2904657106 hasConcept C59491497 @default.
• W2904657106 hasConcept C71924100 @default.
• W2904657106 hasConcept C95190672 @default.
• W2904657106 hasConceptScore W2904657106C126322002 @default.
• W2904657106 hasConceptScore W2904657106C142724271 @default.
• W2904657106 hasConceptScore W2904657106C177713679 @default.
• W2904657106 hasConceptScore W2904657106C197934379 @default.
• W2904657106 hasConceptScore W2904657106C204787440 @default.
• W2904657106 hasConceptScore W2904657106C23131810 @default.
• W2904657106 hasConceptScore W2904657106C27081682 @default.
• W2904657106 hasConceptScore W2904657106C2776478404 @default.
• W2904657106 hasConceptScore W2904657106C2778360308 @default.
• W2904657106 hasConceptScore W2904657106C2778715236 @default.
• W2904657106 hasConceptScore W2904657106C2909182145 @default.
• W2904657106 hasConceptScore W2904657106C59491497 @default.
• W2904657106 hasConceptScore W2904657106C71924100 @default.
• W2904657106 hasConceptScore W2904657106C95190672 @default.
• W2904657106 hasFunder F4320307779 @default.
• W2904657106 hasIssue "1" @default.
• W2904657106 hasLocation W29046571061 @default.
• W2904657106 hasLocation W29046571062 @default.
• W2904657106 hasOpenAccess W2904657106 @default.
• W2904657106 hasPrimaryLocation W29046571061 @default.
• W2904657106 hasRelatedWork W102870620 @default.
• W2904657106 hasRelatedWork W2125552220 @default.
• W2904657106 hasRelatedWork W2377731693 @default.
• W2904657106 hasRelatedWork W2908362781 @default.
• W2904657106 hasRelatedWork W2921326516 @default.
• W2904657106 hasRelatedWork W3014370677 @default.
• W2904657106 hasRelatedWork W3202683323 @default.
• W2904657106 hasRelatedWork W4205872014 @default.
• W2904657106 hasRelatedWork W4316923544 @default.

• next